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Background
The kinetics of cellular and humoral immune responses
was evaluated in a macaque model after early introduc-
tion of antiretroviral treatment. Twelve cynomolgus
macaques were infected intravenously with the patogenic
SIVmac239 strain. Treatment with the antiretroviral drug
Tenofovir was initiated 10 days after inoculation with
SIVmac239 and was administered subcutaneously as daily
injections for 4 months.
Methods
Viral load, CD4 counts and cellular immune responses
were assessed by measuring proliferation and cytokine
production by ELISpot as well as intracellular cytokine
staining. Flow cytometry analyses were performed to
assess T cell activation and memory T cell populations. In
addition, the emergence of neutralizing antibodies was
monitored throughout the study.
Results
Unexpectedly many macaques were able to keep good
viral control (7/12) for 16 months after stopping Tenofo-
vir and kept their CD4 T cell numbers. The majority of
animals had substantial immune responses in terms of
proliferative capacity and IFN-gamma production upon
re-stimulation with SIV antigens in vitro. In addition, we
demonstrate that infection of 12 cynomolgus macaques
with SIVmac239 leads to early induction of neutralizing
antibodies against SIVsm (strain SMM3). Neutralizing
titres exceeded 1:640 in all monkeys by 4.5 months post
infection and were as high as 1:10240 in three monkeys.
Conclusion
Early initiation (here 10 days) of effective antiretroviral
treatment seem to have preserved cellular immune
responses in terms of cell numbers, proliferative capacity
and IFN-gamma production. It is conceivable that cellular
immune responses may have contributed to the long-term
control of viral load in a large proportion (7/12) of ani-
mals in the present study and in addition have provided
sufficient help for induction of neutralizing antibodies.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P23 doi:10.1186/1742-4690-6-S3-P23
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P23
© 2009 Makitalo et al; licensee BioMed Central Ltd. 